View of Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials

Return to Article Details Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials Download Download PDF